FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Daniel Safer

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Geographic Areas

Activities & Behaviors

Co-author Network

Publications

TOP 3
Julie M. Zito; Daniel J Safer; Mehmet Burcu; Aloysius Ibe; Laurence S Magder
Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade.
Allen R Tran; Julie M. Zito; Daniel J Safer; Sarah D Hundley
National trends in pediatric use of anticonvulsants.
Daniel J Safer; Julie M. Zito; Alan M Safer
Age-grouped differences in bipolar mania.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Daniel Safer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Julie M. Zito; Daniel J Safer; Mehmet Burcu; Aloysius Ibe; Laurence S Magder
Antipsychotic use by medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade.
Psychiatric services (Washington, D.C.) 2013;64(3):223-9.
2012: Allen R Tran; Julie M. Zito; Daniel J Safer; Sarah D Hundley
National trends in pediatric use of anticonvulsants.
Psychiatric services (Washington, D.C.) 2012;63(11):1095-101.
2012: Daniel J Safer; Julie M. Zito; Alan M Safer
Age-grouped differences in bipolar mania.
Comprehensive psychiatry 2012;53(8):1110-7.
2011: Daniel J Safer
Age-grouped differences in adverse drug events from psychotropic medication.
Journal of child and adolescent psychopharmacology 2011;21(4):299-309.
2010: Daniel J Safer
Mood swing and mood stabilizer: how specific are these terms?
Bipolar disorders 2010;12(7):685-90.
2010: Satish Valluri; Julie M. Zito; Daniel J Safer; Ilene Harris Zuckerman; C. Daniel Mullins; James J Korelitz
Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression.
Medical care 2010;48(11):947-54.
2009: Daniel J Safer
Irritable mood and the Diagnostic and Statistical Manual of Mental Disorders.
Child and adolescent psychiatry and mental health 2009;3(1):35.
2008: Julie M. Zito; Daniel J Safer; Lolkje T W de Jong-van den Berg; Katrin Janhsen; Jörg M Fegert; James F Gardner; Gerd Glaeske; Satish C Valluri
A three-country comparison of psychotropic medication prevalence in youth.
Child and adolescent psychiatry and mental health 2008;2(1):26.
2008: Julie M. Zito; Albert T Derivan; Christopher J Kratochvil; Daniel J Safer; Jörg M Fegert; Laurence L Greenhill
Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring.
Child and adolescent psychiatry and mental health 2008;2(1):24.
2008: Julie M. Zito; Daniel J Safer; Devadatta Sai; James F Gardner; Diane Thomas; Phyllis Coombes; Melissa Dubowski; Maria Mendez-Lewis
Psychotropic medication patterns among youth in foster care.
Pediatrics 2008;121(1):e157-63.
2007: Julie M. Zito; Daniel J Safer
Is there a connection between methylphenidate and cancer in youth?
Pharmacoepidemiology and drug safety 2007;16(12):1273-4.
2007: Julie M. Zito; Daniel J Safer; Satish Valluri; James F Gardner; James J Korelitz; Donald R Mattison
Psychotherapeutic medication prevalence in Medicaid-insured preschoolers.
Journal of child and adolescent psychopharmacology 2007;17(2):195-203.
2007: Daniel J Safer; Julie M. Zito
Do antidepressants reduce suicide rates?
Public health 2007;121(4):274-7.
2006: Julie M. Zito; Hilde Tobi; Lolkje T W de Jong van den Berg; Jörg M Fegert; Daniel J Safer; Katrin Janhsen; Dorte Gilså Hansen; James F Gardner; Gerd Glaeske
Antidepressant prevalence for youths: a multi-national comparison.
Pharmacoepidemiology and drug safety 2006;15(11):793-8.
2006: Daniel J Safer
Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders?
Pediatrics 2006;118(3):1248-51.
2006: Julie M. Zito; Daniel J Safer; James F Gardner; Karen Soeken; Jae Ryu
Anticonvulsant treatment for psychiatric and seizure indications among youths.
Psychiatric services (Washington, D.C.) 2006;57(5):681-5.
2006: Daniel J Safer; Julie M. Zito
Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents.
Journal of child and adolescent psychopharmacology 2006;16(1-2):159-69.
2005: Susan DosReis; Julie M. Zito; Daniel J Safer; James F Gardner; Karen B Puccia; Pamela L Owens
Multiple psychotropic medication use for youths: a two-state comparison.
Journal of child and adolescent psychopharmacology 2005;15(1):68-77.
2005: Julie M. Zito; Daniel J Safer
Recent child pharmacoepidemiological findings.
Journal of child and adolescent psychopharmacology 2005;15(1):5-9.
2005: Julie M. Zito; Daniel J Safer; Ilene Harris Zuckerman; James F Gardner; Karen Soeken
Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths.
Psychiatric services (Washington, D.C.) 2005;56(2):157-63.
2004: Daniel J Safer; Julie M. Zito; James F Gardner
Comparative prevalence of psychotropic medications among youths enrolled in the SCHIP and privately insured youths.
Psychiatric services (Washington, D.C.) 2004;55(9):1049-51.
2004: Daniel J Safer
A comparison of risperidone-induced weight gain across the age span.
Journal of clinical psychopharmacology 2004;24(4):429-36.
2003: Susan DosReis; Julie M. Zito; Daniel J Safer; Karen Soeken; John W Mitchell; Leslie C Ellwood
Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder.
Journal of developmental and behavioral pediatrics : JDBP 2003;24(3):155-62.
2003: Daniel J Safer; Julie M. Zito; Susan DosReis
Concomitant psychotropic medication for youths.
The American journal of psychiatry 2003;160(3):438-49.
2003: Julie M. Zito; Daniel J Safer; Susan DosReis; James F Gardner; Laurence S Magder; Karen Soeken; Myde Boles; Frances L. Lynch; Mark A Riddle
Psychotropic practice patterns for youth: a 10-year perspective.
Archives of pediatrics & adolescent medicine 2003;157(1):17-25.
2002: Daniel J Safer
Design and reporting modifications in industry-sponsored comparative psychopharmacology trials.
The Journal of nervous and mental disease 2002;190(9):583-92.
2002: Daniel J Safer; Julie M. Zito
Adolescent stimulant use.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2002;167(1):15; author reply 15-6.
2002: Julie M. Zito; Daniel J Safer; Susan DosReis; James F Gardner; Karen Soeken; Myde Boles; Frances L. Lynch
Rising prevalence of antidepressants among US youths.
Pediatrics 2002;109(5):721-7.
2001: Susan DosReis; Julie M. Zito; Daniel J Safer; Karen Soeken
Mental health services for youths in foster care and disabled youths.
American journal of public health 2001;91(7):1094-9.
2001: Julie M. Zito; Daniel J Safer
Services and prevention: pharmacoepidemiology of antidepressant use.
Biological psychiatry 2001;49(12):1121-7.
2001: Daniel J Safer; Julie M. Zito; J E Gardner
Pemoline hepatotoxicity and postmarketing surveillance.
Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(6):622-9.
2001: Julie M. Zito; Daniel J Safer
Antidepressant treatment in children and adolescents: bridging the gap between efficacy and effectiveness.
Current psychiatry reports 2001;3(2):115-25.
2000: Daniel J Safer; M Malever
Stimulant treatment in Maryland public schools.
Pediatrics 2000;106(3):533-9.
2000: Daniel J Safer
Are stimulants overprescribed for youths with ADHD?
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2000;12(1):55-62.
2000: Julie M. Zito; Daniel J Safer; Susan DosReis; James F Gardner; Myde Boles; Frances L. Lynch
Trends in the prescribing of psychotropic medications to preschoolers.
JAMA : the journal of the American Medical Association 2000;283(8):1025-30.
1999: Julie M. Zito; Daniel J Safer; Susan DosReis; Laurence S Magder; James F Gardner; DA Zarin
Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder.
Archives of pediatrics & adolescent medicine 1999;153(12):1257-63.
1998: Julie M. Zito; Daniel J Safer; Susan DosReis; Mark A Riddle
Racial disparity in psychotropic medications prescribed for youths with Medicaid insurance in Maryland.
Journal of the American Academy of Child and Adolescent Psychiatry 1998;37(2):179-84.
1998: Julie M. Zito; Daniel J Safer; Mark A Riddle; R E Johnson; S M Speedie; MICHAEL FOX
Prevalence variations in psychotropic treatment of children.
Journal of child and adolescent psychopharmacology 1998;8(2):99-105.
1997: Daniel J Safer
Self-reported suicide attempts by adolescents.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 1997;9(4):263-9.
1997: Daniel J Safer
Adolescent/adult differences in suicidal behavior and outcome.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 1997;9(1):61-6.
1997: Daniel J Safer
Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s.
Journal of child and adolescent psychopharmacology 1997;7(4):267-74.
1997: Julie M. Zito; Daniel J Safer
Sources of data for pharmacoepidemiological studies of child and adolescent psychiatric disorders.
Journal of child and adolescent psychopharmacology 1997;7(4):237-53.
1997: Julie M. Zito; Daniel J Safer; Susan DosReis; Laurence S Magder; Mark A Riddle
Methylphenidate patterns among Medicaid youths.
Psychopharmacology bulletin 1997;33(1):143-7.
1996: Daniel J Safer; Julie M. Zito; E M Fine
Increased methylphenidate usage for attention deficit disorder in the 1990s.
Pediatrics 1996;98(6 Pt 1):1084-8.
1996: Daniel J Safer
A comparison of studies from the United States and western Europe on psychiatric hospitalization referrals for youths exhibiting suicidal behavior.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 1996;8(3):161-8.
1995: Daniel J Safer
Major treatment considerations for attention-deficit hyperactivity disorder.
Current problems in pediatrics 1995;25(4):137-43.
1995: Daniel J Safer
An outpatient/inpatient comparison of child psychiatric diagnosis.
The American journal of orthopsychiatry 1995;65(2):298-303.
1994: Daniel J Safer; J M Krager
The increased rate of stimulant treatment for hyperactive/inattentive students in secondary schools.
Pediatrics 1994;94(4 Pt 1):462-4.
1994: Daniel J Safer
The impact of recent lawsuits on methylphenidate sales.
Clinical pediatrics 1994;33(3):166-8.
1992: Daniel J Safer; J M Krager
Effect of a media blitz and a threatened lawsuit on stimulant treatment.
JAMA : the journal of the American Medical Association 1992;268(8):1004-7.
1992: Daniel J Safer
Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder.
Journal of child and adolescent psychopharmacology 1992;2(4):279-90.
1991: Daniel J Safer
Diet, behavior modification, and exercise: a review of obesity treatments from a long-term perspective.
Southern medical journal 1991;84(12):1470-4.
1989: Daniel J Safer; Richard Allen
Absence of tolerance to the behavioral effects of methylphenidate in hyperactive and inattentive children.
The Journal of pediatrics 1989;115(6):1003-8.
1989: Daniel J Safer; J M Krager
Hyperactivity and inattentiveness. School assessment of stimulant treatment.
Clinical pediatrics 1989;28(5):216-21.
1988: Daniel J Safer; J M Krager
A survey of medication treatment for hyperactive/inattentive students.
JAMA : the journal of the American Medical Association 1988;260(15):2256-8.
1987: Daniel J Safer
Substance abuse by young adult chronic patients.
Hospital & community psychiatry 1987;38(5):511-4.
1986: Daniel J Safer
Nonpromotion correlates and outcomes at different grade levels.
Journal of learning disabilities 1986;19(8):500-3.
1985: Daniel J Safer; J M Krager
Prevalence of medication treatment for hyperactive adolescents.
Psychopharmacology bulletin 1985;21(2):212-5.
1984: Daniel J Safer
Subgrouping conduct disordered adolescents by early risk factors.
The American journal of orthopsychiatry 1984;54(4):603-12.
1983: Daniel J Safer
Broader clinical considerations in child psychopharmacology practice.
Comprehensive psychiatry 1983;24(6):567-73.
1983: Daniel J Safer; J M Krager
Trends in medication treatment of hyperactive school children. Results of six biannual surveys.
Clinical pediatrics 1983;22(7):500-4.
1981: Daniel J Safer; R C Heaton; F C Parker
A behavioral program for disruptive Junior High school students: results and follow-up.
Journal of abnormal child psychology 1981;9(4):483-94.
1979: J M Krager; Daniel J Safer; J Earhart
Follow-up survey results of medication used to treat hyperactive school children.
The Journal of school health 1979;49(6):317-21.
1976: R C Heaton; Daniel J Safer; Richard Allen; N C Spinnato; F M Prumo
A motivational environment for behaviorally deviant junior high school students.
Journal of abnormal child psychology 1976;4(3):263-75.
1975: Daniel J Safer; Richard Allen
Stimulant drug treatment of hyperactive adolescents.
Diseases of the nervous system 1975;36(8):454-7.
1975: Richard Allen; Daniel J Safer; LINO COVI
Effects of psychostimulants on aggression.
The Journal of nervous and mental disease 1975;160(2-1):138-45.
1975: Richard Allen; Daniel J Safer; R Heaton; A Ward; M Barrell
Behavior therapy for socially ineffective children.
Journal of the American Academy of Child Psychiatry 1975;14(3):500-9.
1975: Daniel J Safer; Richard Allen; E Barr
Growth rebound after termination of stimulant drugs.
The Journal of pediatrics 1975;86(1):113-6.
1974: J M Krager; Daniel J Safer
Type and prevalence of medication used in the treatment of hyperactive children.
The New England journal of medicine 1974;291(21):1118-20.
1974: Daniel J Safer
Factors affecting outcome in a school mental health service.
Community mental health journal 1974;10(1):24-32.
1973: Daniel J Safer; Richard Allen
Single daily dose methylphenidate in hyperactive children.
Diseases of the nervous system 1973;34(6):325-8.
1973: Daniel J Safer; Richard Allen
Drug comparison in hyperactive children.
The American journal of psychiatry 1973;130(8):939-40.
1973: Daniel J Safer
"A familial factor in minimal brain dysfunction.
Behavior genetics 1973;3(2):175-86.
1973: Daniel J Safer; Richard Allen
Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children.
Pediatrics 1973;51(4):660-7.
1972: Daniel J Safer; Richard Allen; E Barr
Depression of growth in hyperactive children on stimulant drugs.
The New England journal of medicine 1972;287(5):217-20.
1971: Daniel J Safer
Drugs for problem school children.
The Journal of school health 1971;41(9):491-5.
1971: Daniel J Safer; Richard Allen
The central effects of scopolamine in man.
Biological psychiatry 1971;3(4):347-55.
1971: Daniel J Safer; Richard Allen
The effect of fluphenazine in psychologically normal volunteers: some temporal, performance, and biochemical relationships.
Biological psychiatry 1971;3(3):237-49.
1970: Daniel J Safer
The effect of heat, cold, and work on the central actions of scopolamine.
Clinical pharmacology and therapeutics 1970;11(1):60-7.
1970: Daniel J Safer
The concomitant effects of mild sleep loss and an anticholinergic drug.
Psychopharmacologia 1970;17(5):425-33.
1970: Daniel J Safer
The effect of LSD on sleep-deprived men.
Psychopharmacologia 1970;17(5):414-24.
1968: Daniel J Safer
Establishing boundary lines for families of children with behavior disorders.
The Psychiatric quarterly. Supplement 1968;42 Pt 1():86-97.
1965: Daniel J Safer
Conjoint play therapy for the young child and his parent.
Archives of general psychiatry 1965;13(4):320-6.